Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors

George Mellgard(Memorial Sloan Kettering Cancer Center), Che‐Kai Tsao(Mount Sinai Hospital), Xiaobo Zhong(Icahn School of Medicine at Mount Sinai), Philip Garcia(Icahn School of Medicine at Mount Sinai), Parissa Alerasool(New York Medical College), Amanda Leiter(Icahn School of Medicine at Mount Sinai), Himanshu Joshi(Icahn School of Medicine at Mount Sinai), Tomi Jun(Sema4 (United States)), Mahalya Gogerly-Moragoda(Icahn School of Medicine at Mount Sinai), Qian Qin(The University of Texas Southwestern Medical Center), Emily J. Gallagher(Icahn School of Medicine at Mount Sinai), Vaibhav G. Patel(Icahn School of Medicine at Mount Sinai), William Oh(Women & Infants Hospital of Rhode Island), Anish B. Parikh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Bo Wang(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai)
Journal of Cancer Research and Clinical Oncology
July 5, 2022
10.1007/s00432-022-04159-y
Cited by 23

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network
|PEDIATRICS|2002|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k